More specifically, human settlement of Remote Oceania occurred recently and linguistic
and archeological evidence points toward an origin from Asia or Near Oceania (Melanesia), respectively.27 Previous tMRCA estimates (6.2–12.0 ka for Y chromosome and 5.1–8.1 ka for mtDNA), in addition to the double origin of the Polynesians, were used as the major hypotheses to be tested by our molecular clock analyses of HBV.19 Our first calibration point, which was placed at the root node of the F/H genotypes from the Amerindians, allowed us to accurately recover the previously mentioned coalescence times of Polynesian populations (Table 1). The molecular clock analysis using the additional younger calibration points (i.e., D4 subgenotype and A5 clade from Haiti; see Materials RO4929097 price and Methods and Supporting Information) gave an estimate for the substitution rate of HBV of 2.2 × 10−6 (95% higher posterior density [95% HPD]: 1.5−3.0 × 10−6) substitutions/site/year. Our estimate for the tMRCA of HBV in humans was therefore 33.6 ka (95% HPD: 22.0–47.1 ka) (Table 2). The median tMRCAs for most HBV genotypes (A,
B, D, and F) are similar to each other (Table 2), ranging from 8.9 to 12.7 ka (Table 2; Figs. 1-3; Supporting Figs. S2-S4). Genotype C was the oldest, due to the inclusion of the outlier “Aboriginal” strains (median estimate 26.2 ka; Fig. 2). In contrast, genotypes E, H, and G appeared much more recently, although considerable differences were CB-839 molecular weight observed in their median tMRCAs (0.7–6.0 ka; Table 2). Is there evidence that HBV is evolving so slowly? Notably, in a recent study Bar-Gal et al.28
described the detection and molecular characterization of HBV DNA isolated from a Korean child naturally mummified in the 16th century A.D. This finding provides the first physical evidence that humans were infected with HBV at least 400 years ago, but also allows us to check if our molecular clock findings are medchemexpress consistent. The ancient sequence from the Korean mummy was not an outlier to the most recent HBV subgenotype C2 sequences (Fig. 2), confirming that HBV is a slow-evolving pathogen and that its clades (genotypes and subgenotypes) were shaped long before the 16th century A.D. The estimated population history of HBV, measured as the product of the effective number of infections and generation time (NeT) (Fig. 4), suggests that the most pronounced period of growth began about 5.0 ka years ago and lasted for at least 4,000 years. The exponential phase in the HBV epidemic coincides with the population expansion of modern humans over the past 5,000 years, during which the global population increased from 15 million to 3,000 million (P < 0.001) (Fig. 4).29,30 Is there any similarity between the HBV and human populations’ phylogeny to support co-cladogenesis of HBV and human? If so we would be able to see the formation of HBV clades coinciding with the formation of clades in the human phylogenetic tree.